Left Ventricular Ejection Fraction clinical trials at UCSF
1 research study open to eligible people
Left ventricular ejection fraction is the percentage of blood pumped out of the heart's left chamber with each beat. UCSF is recruiting for trials testing TNX-103, a medicine that might improve exercise ability in patients with heart failure and pulmonary hypertension. These studies aim to compare its effects with a placebo.
Showing trials for
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
open to eligible people ages 18-85
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
San Francisco, California and other locations
Last updated: